Immunometabolism and Cancer Immunotherapy
Young Principal Investigator
|Location|| Building 13 |
Via Adamello 16, Milano
Cancer immunotherapy has been one of the major breakthroughsof cancer treatments. However, despite the impressive results, the incidence of cancer is still raising and the majority of patients will receive little benefit.
In the fight against cancer, CD8+T cells are the soldiers of the immune system which destroy tumor cells. However, they become progressively dysfunctional and no longer able to control tumor outgrowth.
One reason for this dysfunctionality is T cells do not receive adequate fuel for their cytotoxic functions.
Our research group is interested in understanding the link between T cell metabolism and immunity in cancer.
Importantly, our lab focuses on understanding how this dysfunction can be reversed to harness T cells against cancer and improve immunotherapeutic treatment of cancer.
Most Relevant Publications
T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors.
Cancer Res, 2017
OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence.
J Immunol, 2015
Vaccine-instructed intratumoral IFN-γ enables regression of autochthonous mouse prostate cancer in allogeneic T-cell transplantation.
Cancer Res, 2013